SOPHiA GENETICS S.A.
NASDAQ:SOPH · NASDAQ Global Select
+$0.02 today
Vol 0.44M · Avg 0.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-167.6%
avg -68.2%
ROIC
-61.3%
avg -42.7%
ROA
-48.3%
avg -35.1%
Analysis
ROA is currently the strongest return metric at -48.3% versus its period average of -35.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jurgi Camblong | Co-Founder, Chief Executive Officer & Director | $1.23M | — | 47 | $3.62M | 5.05% |
Philippe Menu | Executive Vice President, Chief Medical Officer & Chief Product Officer | — | — | 44 | $245,780.00 | 0.34% |
Zhenyu Xu | Executive Vice President & Chief Scientific Officer | — | — | 43 | $622,280.00 | 0.87% |
Abhimanyu Verma | EVP & Chief Technology Officer | — | — | — | $204,400.00 | 0.29% |
Daan van Well | Executive VP and Chief Legal & Compliance Officer | — | — | 51 | $345,052.00 | 0.48% |
George A. Cardoza | Executive Vice President & Chief Financial Officer | — | — | 64 | $311,458.00 | 0.43% |
Kevin Puylaert | SVP & Chief Sales Officer | — | — | — | $148,164.00 | 0.21% |
Kellen Sanger | Head of Strategy and Investor Relations | — | — | — | — | — |
Ross Jordan Muken | President | — | — | 45 | $680,911.00 | 0.95% |
Manuela Da Silva Valente | Executive Vice President & Chief People Officer | — | — | 55 | $214,691.00 | 0.30% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$99,000.00
Sells
80
$1.24M
Net Sentiment
$1.14M
Net selling
Most Active
Menu Philippe
15 transactions
1–10 of 81
Analysis
Insiders reported 1 buys worth $99,000.00 and 80 sells worth $1.24M over the last 12 months. That adds up to net selling of $1.14M. Menu Philippe was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +30.0% | +21.0% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +30.0% over three years. Forward estimates point to Revenue at +21.0% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.80B
Alto Neuroscience, Inc.
NYSE:ANRO
$778.73M
National Research Corporation
NASDAQ:NRC
$401.27M
Simulations Plus, Inc.
NASDAQ:SLP
$369.15M
Cellectis S.A.
NASDAQ:CLLS
$311.28M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$300.45M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
OptimizeRx Corporation
NASDAQ:OPRX
$94.01M
Definitive Healthcare Corp.
NASDAQ:DH
$85.40M
Nakamoto Inc.
NASDAQ:NAKA
$72.13M
Who manages SOPH?
SOPHiA GENETICS S.A. (SOPH) lists 10 active executives. The top listed executive is Jurgi Camblong, Co-Founder, Chief Executive Officer & Director.
Are SOPH insiders buying or selling?
Recent insider activity shows net buying of $9.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.